WR-1065 is a cytoprotective cell-permeable ROS scavenge and an active metabolite of Amifostine.
WR-1065 is cytoprotective cell-permeable reactive oxygen species scavenger and p53 activator and re-activator. Recently shown to have antiretroviral activity and an active metabolite of Amifostine which selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy.
WR-1065 is the active metabolite of the prodrug amifostine, generated by alkaline phosphatase. It is found to accumulate in many epithelial tissues. WR-1065 protects cellular membranes and DNA from free radical induced damage.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1049-1057 (2010-01-28)
We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters. We assessed the pharmacokinetics of
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer
Thiol and aminothiol compounds are among the most efficient chemical radioprotectors. To increase their efficiency, we synthesized two new classes of thiol and aminothiol compounds derived from benzothiazole (T1, T2, AM1, AM2) and thiadiazole (T3, T4, AM3) structures. We examined
